Expanding Adenoviral Vectors to Novel Therapeutic Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of adenoviral vectors derived from chimpanzee adenovirus to address unmet needs in cancer treatment, gene therapy, neurodegenerative diseases, livestock health, and regenerative medicine.
Background and Problem Solved
The original patent disclosed adenoviral vectors for vaccine applications, but these vectors have untapped potential in other therapeutic areas. The new inventive concept addresses the limitations of traditional treatment approaches in these fields by harnessing the unique properties of chimpanzee adenovirus-derived vectors.
Detailed Description of the Inventive Concept
The new inventive concept involves engineering adenoviral vectors derived from chimpanzee adenovirus to selectively target and destroy cancer cells, cross the blood-brain barrier for gene therapy, express neuroprotective proteins for neurodegenerative diseases, express antigens for livestock health, and promote tissue regeneration and repair. These vectors can be tailored to specific disease indications and administered via various routes to achieve optimal therapeutic outcomes.
Novelty and Inventive Step
The new inventive concept's novelty lies in its application of chimpanzee adenovirus-derived vectors to novel therapeutic areas, which was not contemplated in the original patent. The inventive step resides in the innovative engineering of these vectors to address specific disease needs and overcome existing treatment limitations.
Alternative Embodiments and Variations
Alternative embodiments may include using different serotypes of chimpanzee adenovirus, incorporating additional genetic elements, or combining these vectors with other therapeutic modalities. Variations may involve targeting different disease indications or developing novel vector delivery systems.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in various industries, including oncology, neurology, veterinary medicine, and regenerative medicine. The target market includes pharmaceutical and biotechnology companies, research institutions, and hospitals seeking innovative solutions for unmet medical needs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K48/00 |
| C | C12 | C12N5/0606 |
| C | C12 | C12N7/00 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/10021 |
| C | C12 | C12N2710/10042 |
| C | C12 | C12N2710/10044 |
| C | C12 | C12N2800/204 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular virology, gene therapy, and recombinant vector engineering, with expertise in adenoviral vector design, genetic modification, and therapeutic applications across multiple domains including infectious disease, oncology, and regenerative medicine
Person of Ordinary Skill (PHOSITA) Profile
A molecular biologist or virologist with advanced degree, experienced in genetic engineering techniques, vector design, understanding of viral genome manipulation, and familiarity with vector-based therapeutic strategies
Obviousness Rationale
A PHOSITA would recognize that the core adenoviral vector technology from the source patent provides a foundational platform for exploring diverse therapeutic applications. The disclosed variations represent predictable extensions of known vector engineering principles, leveraging the established chimpanzee adenovirus vector framework to address specific disease targeting and genetic modification challenges. The technical modifications proposed in the PTD are consistent with standard vector engineering approaches and would be considered routine optimization within the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,640 |
|---|---|
| Title | Simian adenovirus and hybrid adenoviral vectors |
| Assignee(s) | OXFORD UNIVERSITY INNOVATION LIMITED |